Oxford Immunotec announces approval of $100M share repurchase program
Oxford Immunotec announced that its Board of Directors has approved a share purchase program, which would involve the purchase of up to $100M of the company's outstanding ordinary shares over a five-year period. The share purchase program, which is subject to shareholder approval, will be presented for shareholder approval on or before the company's annual general meeting of shareholders on Tuesday, June 18, 2019. Share repurchases, if any, will be made in the open market or in any private transaction, from time-to-time and in accordance with applicable laws, rules and regulations. The timing and actual number of shares repurchased will depend on a variety of factors including price, market conditions and applicable legal requirements. The share repurchase program does not obligate the company to repurchase any specific number of shares and may be suspended or terminated at any time without prior notice. As announced previously, Peter Wrighton-Smith, will present at the 37th Annual JPMorgan Healthcare Conference on Wednesday, January 9, 2019. Wrighton-Smith will reaffirm fourth quarter 2018 growth expectations previously communicated, including double-digit T-SPOT.TB test volume growth in the U.S., strong year-over-year revenue growth in Asia, and an acceleration in year-over-year revenue growth in Europe & ROW.